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ABSTRACT
Obesity has become a global health issue and is one of the factors that trigger degenerative diseases. The 
correct food consumption management could be a solution for treating obesity. Soybean is a food that is 
rich in bioactive components and has antiobesity properties through various mechanisms. In Indonesia, 
nearly 60% of the soybeans are consumed in the form of tempe. The process of fermenting soybeans into 
tempe causes a bioconversion of nutrients and bioactive components, improving the active physiological 
abilities. The bioactive components that play a role in the treatment of obesity are isoflavones, proteins, 
and peptides. These bioactive components help in reducing body weight, lowering the body fat ratio and 
improve lipid profile. Thus, optimation and popularization of tempe as a functional food in the daily 
menu supported with correct tempe processing could be a solution in treating obesity. 
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INTRODUCTION
Obesity has become a worldwide health is-
sue and is believed to be one of the factors that 
trigger degenerative diseases and metabolic prob-
lems such as diabetes mellitus (DM), coronary 
heart diseases (CHD), dyslipidemia, hyperten-
sion, and arthritis (Yuliana et al. 2011; Velasquez 
& Bhathena 2007). WHO (2014) highlighted that 
65% of the world population is overweight and 
obese and has a higher mortality risk than mal-
nourished people. Based on the WHO standard, 
a BMI greater than 25 kg/m2 is categorized as 
overweight, and a BMI greater than 30 kg/m2 is 
categorized as obese.
Aside from the lack of physical activities, 
poor food consumption pattern such as excessive 
consumption of foods rich in fat and carbohydrate 
is considered as a main cause of obesity (WHO 
2011). Therefore, strategies in treating obesity in-
clude reduction of the amount of energy absorbed 
by the body, using appetite suppressants, inhibit-
ing nutrient absorption, increasing metabolism, 
and lipid modulation (inhibiting the differentia-
tion and proliferation of adipocytes, and reducing 
lipogenesis and increasing lipolysis) (Yun 2010). 
Complications due to obesity and other 
degenerative diseases have encouraged the con-
sumption of low-energy, low-fat, high-fiber, and 
antioxidant-rich foods (Bhathena & Velasquez 
2002). Soybeans have been reported to contain 
such quality, it has various bioactive components 
which have active physiological properties in 
treating obesity (Bhathena & Velasquez 2002; 
Velasquez & Bhathena 2007). In Indonesia, near-
ly 60% of soybeans are consumed in the form 
of tempe with an average tempe consumption 
of 10.1 kg per person per year (Astawan et al. 
2017). The process of fermenting soybeans into 
tempe can also improve its nutritional value and 
benefits for health (Nout & Kries 2005; Astawan 
2008). 
Many studies pertaining to the use of soy-
beans and soybean products in the treatment of 
obesity have been conducted, however not many 
discuss the possibilities of utilizing tempe which 
is a fermented soybean product as a component 
in treating obesity. Against this backdrop, the re-
view will discuss the possibilities of using tempe 
as a soybean-derived functional food in the treat-
ment of obesity.
1. The Bioactive components of soybeans and 
tempe
The main ingredient of tempe is soybeans 
(Glycine max), therefore bioactive components 
of soybeans (Table 1) would most likely be found 
in tempe, or might even be more “activated” due 
to the fermentation process. Tempe is made from 
soybean through a number of steps, namely soak-
ing, boiling, removing the cotyledon husk, add-
ing mold (the mold Rhizopus spp.), and ferment-
ing at 30-37°C for 36-48 hours (Nout & Kries 
2005). Fermentation changes various compo-
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nents in soybeans, producing tempe which has 
an enhanced nutritional content and improved 
bioactive components and is more beneficial for 
health than soybeans (Astawan et al. 2017). Table 
1 shows the bioactive components in soybean and 
the benefit for health. 
The technology of tempe-making is “ad-
opted” in food technology as the term Solid State 
Bioconversion (SSB) or Solid State Fermentation 
(SSF) by exploiting various molds which are usu-
ally used in traditional fermentation processes 
such as Rhizopus sp, Aspergillus sp., Bacillus 
sp., et cetera (Maiti & Majumdar 2012; McCue 
et al . 2005; Sanchez-Magana et al. 2014). Fer-
mentation of soybeans using the mold Rhizopus 
spp. is favored because the application is simple 
and able to produce products with a palatable fla-
vor (Sanchez-Magana et al. 2014; Wijaya et al. 
2007).
Fermentation will increase the content 
of small molecules such as free fatty acids and 
amino acids (Ali et al. 2016) and the isoflavone 
aglycone (Haron et al. 2009), as well as produce 
bioactive peptides (Gibbs et al. 2004). This is 
due to the enzymatic activity of microorganisms 
which works on the soybean substrate, for exam-
ple, lactic acid bacteria (BAL), mold, and yeast 
(Gibbs et al. 2004; Barus et al. 2008). Singh et 
al. (2014) reported that fermentation with BAL 
is also commonly used for the production of bio-
active peptides. These bioactive components will 
lend active physiological properties for health.
The amount and types of bioactive compo-
nents produced during the fermentation of tempe 
are influenced by the enzymatic activities of the 
microorganisms. Efriwati and Nuraida (2013) 
demonstrated that differences during the tempe 
production process will yield different mac-
ronutrient components (carbohydrate, fat, and 
protein) in the tempe and also differences in the 
isoflavone content. Differences in the tempe pro-
duction method create a possibility for different 
microbes to exist and to take part in the tempe 
fermentation process (Barus et al. 2008). The dif-
ferences in microorganisms will determine the 
differences in proteolytic, lipolytic, and glycolyt-
ic activities, and these will determine differences 
in the bioconversion of fat, protein, carbohydrate 
and other components (Tope 2014). 
A number of in vitro tests revealed a few 
bioactive components in soybeans and products 
derived from soybeans that play a role in the 
treatment of obesity such as phenolic (isoflavone) 
component and peptides. Some of the mecha-
nisms of these components can be seen in Table 
2. 
Table 1. The bioactive components in soybeans and the benefits for health (Sugano 2006)
Component Health benefits 
Protein Hypocholesterolemic, antiatherogenic, reduces weight 
Peptide Easily absorbed, reduces weight
Lectin Immunity, anticarcinogenic
Trypsin inhibitor Anticarcinogenic 
Dietary fiber Improves the function of the digestive tract, prevents colon cancer, regulates the metabolism 
of fat
Oligosaccharide Prebiotic, improves the function of the digestive tract 
Phytin Regulates carbohydrate metabolism, anticarcinogenic, aids in mineral absorption 
Saponin Regulates fat  metabolism, antioxidant
Isoflavone Esterogen functions, prevents osteoporosis, anticarcinogenic
Linoleic acid Essential fatty acid, hypocholesterolemic 
Linolenic acid Essential fatty acid, hypocholesterolemic, improves the function of the cardiovascular sys-
tem, antiallergy
Lecithin Increases the metabolism of fat, maintains nervous functions 
Tocopherol Antioxidant, prevents cardiovascular diseases 
Sterol Hypocholesterolemic, prevents prostate cancer 
Vitamin K Aids in blood clotting, prevents osteoporosis
Mg Essential mineral, prevents cardiovascular problems 
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Table 2. Bioactive components in tempe for the treatment of obesity 






E peptide and I 
peptide 
Antioxidant through 
the ferric thiocyanate 
method
Positive antioxidant activity, 
and E peptide also has an ACE 
inhibition property with an 
IC50 of 0.6±0.1μM











Maximum inhibition of amy-
lase on day 4 of fermentation 
with an inhibition index (AI) 
of 2.08. Highest glucosidase 
inhibition on day 6 of fermen-
tation, AI=1.1. A correlation of 
R=0.85 between antioxidant 
activity and amylase inhibition 












Highest antioxidant on fermen-
tation day 4, 57.4% higher than 
soybeans without fermenta-
tion,  highest amylase  inhibi-
tion on day 6 of fermentation, 
AI=3.6, highest glucosidase 
inhibition on day 6 of fermen-
tation, AI = 2.0
Maiti and Ma-
jumdar (2012)
1.1. Phenolic component and isoflavone
In Indonesia, soybeans are processed 
into tempe, tofu, soy sauce, tauco, and soymilk. 
Among those soybean products, tempe is the 
food with the highest isoflavone aglycone thus 
provide higher bioavailability compared to other 
soybean products (Haron et al. 2009). Raw tempe 
has an isoflavone content of 54 mg/100 g (bb), 
while tofu and soymilk have a lower isoflavone 
content of 43 and 28 mg/100 g (bb), respectively.
Mold fermentation helps activate the soy-
bean’s isoflavone component (Figure 1) from the 
glycone form (daidzin and genistin) to aglycone 
(daidzein and genistein) that are more readily 
absorbed by the body (Astawan 2008) and also 
increases the antioxidant activity (Astawan et al. 
2013). Efriwati and Nuraida (2013) found that 
the genistein and daidzein contents of tempe were 
9.4-10.0 and 93.4-101.2 mg/100 g tempe (b.k), 
respectively. Haron et al. (2009) found that the 
total isoflavone aglycone was 54 mg/100 g tempe 
(b.k) with almost identical amounts of daidzein 
and genistein, 26±6 mg and 28±11 mg.
The bioconversion of glycone isoflavone 
and the improved bioavailability of isoflavone 
would increase the active physiological proper-
ties of tempe in comparison to soybean, for ex-
ample in condition such as hypotriacylglycerol 
(Watanabe et al. 2006) and hypocholesterolemic 
(Astuti 1997) that usually occur in obesity cases. 
Figure 1 shows the chemical structure of soybean 
isoflavones according to Shao et al. (2009).
Isoflavones also play many roles in the 
inhibition of carbohydrate-digesting enzymes. 
Lee and Lee (2001) demonstrated that genistein 
is an effective α-glucosidase enzyme inhibitor, 
is reversible, slow-binding and non-competitive. 
The product of soybean fermentation using R. 
oligosporus demonstrated an amylase inhibition 
of 1.5-2.0 AI (Amylase Inhibition Index) which 
correlated with the total phenol value (R=0.59) 
(McCue et al. 2005; Maiti & Majumdar 2012). 
In addition, Genistein also has a potential 
as an antiobesity through the activation of the 
AMP-activated kinase (AMPK) in the inhibition 
of lipid differentiation (Hwang et al. 2005). Ge-
nistein (20-200 uM) could significantly inhibit 
90% of adipose tissue differentiation from 3T3-
L1 cells and also induce apoptosis (43%) in ma-
ture adipose tissue (Hwang et al. 2005). In vivo 
testing of 0.2% genistein + 0.5% L-carnitine in 
C57BL/6J rats with high-fat feed demonstrated a 
decrease in body weight of 254% after 12 weeks 
of the experiment. This was believed to be due to 
a PPAR activation inhibition mechanism (Yang et 
al. 2006). Numerous benefits of soybean isofla-
vones and their increased amount in tempe create 
an opportunity to utilize tempe in the treatment 
of obesity.
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1.2. Protein and or peptides
Other components of soybeans that play a 
part in obesity treatment are protein and peptides. 
Wang and Huang (1984) discovered a protein 
found in soybean, sunflower seeds, peanuts, and 
cucumber seeds which have an antiobesity poten-
tial through a lipase inhibition mechanism. The 
inhibition effect was strongly influenced by heat 
and the role of protease and was not dependent 
on the amount of the enzyme lipase but depended 
on the amount of substrate. A large amount of 
substrate eliminated the lipase inhibition effect, 
thus in the application, limitation of fat consump-
tion was also required for an optimum lipase in-
hibition benefit.
The lipase inhibition mechanism is be-
lieved to be through the binding of protein on 
the surface of the substrate micelle, preventing 
the normal lipase function which works on the 
interfacial area between the medium (water) and 
the surface of the micelle (Wang & Huang 1984). 
This soybean protein component is believed to 
still be present in tempe, or the lipase inhibition 
activity in tempe could still be maintained by oth-
er, smaller proteins or peptides produced through 
tempe fermentation. Gibbs et al. (2004) demon-
strated an increase in dissolved protein in tempe 
compared to soybean, plus antioxidant properties 
and other active physiological actvities.
Singh et al. (2014) stated that bioactive 
peptides from soybeans and its products also 
Astawan et al.
have antiobesity properties through a number of 
mechanisms such as anorexia or appetite sup-
pression, inhibition of lipogenesis in the liver 
(decreasing the triglyceride and cholesterol levels 
in the blood), and inhibition of the activation of 
the hormone cholecystokinin (CCK), causing sa-
tiety. Jang et al. (2008) stated that in overweight 
rats induced by high-fat feed, supplementation of 
peptides from black soybeans for 13 weeks has 
shown weight loss, decreased leptin level and de-
creased appetite compared to the controls.  
2. The Effect of soybeans and tempe in obesity 
treatment
A few in vivo studies related to the effect 
of soybean and or tempe consumption on obese 
test animals can be seen in Table 3. Obesity is 
usually associated with insulin resistance and 
abnormalities in lipid metabolism in the form 
of increased overall lipid production such as in-
creased free fatty acids, triglycerides, and LDL 
(Yuliana et al. 2011). Metabolomic issues such 
as dyslipidemia and or diabetes as an effect of 
obesity can be managed by consuming soybeans, 
soybean products such as tempe, or soybean hy-
drolysate as a source of protein. Watanabe et al. 
(2006) and Astawan et al. (2015) demonstrated 
an improvement in lipid profile, especially an in-
crease in HDL due to consumption of tempe feed 
(isocaloric) compared to consumption of casein 
or soybean. 
Figure 1. The chemical structure of soybean isoflavones (Shao et al. 2009)
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Table 3. In vivo studies related to the effect of soybean and or tempe consumption on obesity treatment 
Model Feed and Amount Time Results References
Wistar male rats Three groups: casein, soy-
bean, and tempe-GABA 
with R. microspores inocu-
lum fermented aerobically 
and anaerobically.
Isoprotein (30% ), previ-
ously fed high-fat feed 
(20%)
6 weeks No difference in weight.
A significant difference in cholesterol 
and triacylglyceride levels in plasma, 
namely casein>soybean>tempe-GA-
BA.
The highest HDL in the tempe-GABA 
group.
The highest LDL in the casein group.




rats and yellow 
KK  mice, made 
obese 
Three groups: casein, pro-
tein soybean isolate (SPI), 
and soybean protein hy-
drolysate (SPI-H)
Low-calorie feed (60%), 
high protein (35%) and 
low fat (5%), previously 
fed high-fat feed (30%)
4 weeks Adult rats: lower fat absorption in SPI 
and SPI-H compared to that in casein, 
total cholesterol, and blood glucose 
lower in SPI-H.
Mice: significantly lower body fat in 
SPI and SPI-H than in casein.
A o y a m a 
et al. 2000a
Male yellow 
KK mice, made 
obese 
Four groups: casein 
(WPI), casein hydrolysate 
(WPI-H), soybean protein 
isolate (SPI), and soybean 
protein hydrolysate isolate 
(SPI-H)
Feed as in Aoyama et al. 
2000a
2 weeks A significant descrease in the body 
weight of SPI-H rats compared to WPI 
and WPI-H. Total plasma cholesterol, 
blood glucose, and body fat level lower 
in SPI-H than in WPI and WPI-H. 
A o y a m a 
et al. 2000b
Obese (weight: 
125 g) and nor-
mal (96 g) SHR/
N-cp rats
Fours groups: 20% casein 
(normal), casein +0.1% 
isoflavone, casein +0.1% 





The isoflavone group had a significant 
loss of body weight, epididymal, peri-
renal, subdiaphragmatic, ileal fat pad 
fat weight, and total cholesterol com-
pared to the other treatments in obese 
rats.
Ali et al. 
2004
An experiment using low calorie (60 %), 
high protein (35%) and low fat (5%) feed in obese 
rats demonstrated a decrease in body weight and 
an improvement in the condition of the body 
fat in rats fed with soybean protein isolate and 
soybean hydrolysate compared to those fed with 
casein and milk protein hydrolysate (Aoyama et 
al. 2000a, Aoyama et al. 2000b). The mechanism 
involved were decrease in perirenal fat and blood 
glucose concentration. Furthermore, Kagawa et 
al. (1996) suspected that the fat reduction effect 
was due to the activity of the tetrapeptide found 
in soybeans. 
In addition to protein and or peptides ac-
tivities, the decrease in body weight and the im-
provement in the lipid condition was also due to 
the activity of isoflavone (genistein, daidzein, and 
glycitein) (Ali et al. 2004) found in soybeans and 
tempe. Further, Watanabe et al. (2006) demon-
strated that the protein, isoflavone and free amino 
acid components in tempe had a better hypotriac-
ylglyceride effect than soybeans or casein.
Tempe, which contain protein composition 
that has been fermented into peptides (similar to 
the condition in soybean protein hydrolysate) 
and supported by higher isoflavone component 
than soybeans (Haron et al. 2009) or soybean 
hydrolysate, is of course expected to have more 
benefits for health including for obesity treat-
ment. Unfortunately, no studies in place aimed 
at pertaining to this subject. The author has not 
found any clinical studies regarding the use of 
tempe in humans for the purpose of obesity con-
trol. However, one human study conducted by 
Astuti (1997) has demonstrated the benefits of 
tempe in improving the lipid or dyslipidemia 
status which is also commonly found in obesity 
cases (Table 4). 
Many clinical studies pertaining to the 
use of soybeans in obesity treatment have been 
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conducted. Cope et al. (2008) reported in a re-
view that a number of soybean-based food pro-
ducts will reduce body weight and eliminate fat 
when consumed isocalorically. This was proven 
through in vivo testing using model animals, 
though there are very few supporting clinical 
studies in humans. 
Zhang et al. (2013) have conducted a 
meta-analysis of the efficacy of the consump-
tion of a soybean isoflavone supplement on body 
weight, fasting blood glucose, and insulin in 
post-menopausal non-Asian women. Nine stu-
dies with 528 panelists for the parameter of body 
weight, 11 studies with 1,182 panelists for the 
parameter of blood glucose, and 11 studies with 
1,142 panelists for the parameter insulin have 
been analyzed. These studies have demonstrated 
significant weight loss and a decrease in blood 
glucose and insulin in post-menopausal female 
panelists who had been given isoflavone as a 
supplement compared to the control group which 
was given a placebo. Furthermore, supplementa-
tion of isoflavone for a short time (<6 months) 
could significantly decrease weight, while long-
term supplementation (>6 months) could signifi-
cantly decrease blood glucose. A more significant 
weight loss was achieved through the consump-
tion of a low dosage of supplement (<100 mg) 
and for those who were overweight (BMI <30) 
compared to those who were obese (BMI >30).  
3. Tempe as a functional food in obesity treat-
ment
Considering the various potentials of the 
bioactive components in tempe as an antiobe-
sity, tempe could be made into an appropriate 
diet menu. Yenrina et al. (2006) stated a survey 
of 2,080 households on Java Island revealed that 
they consumed processed soybean products such 
as tofu, tempe, oncom, soybean sprouts, tofu 
skin, and soy sauce in daily basis. Unfortunately, 
many of the processes involved frying, especially 
for tempe.
The frying process would increase fat in-
take (from the cooking oil absorbed by the pro-
duct), indirectly increasing the caloric intake and 
could trigger obesity. Haron et al. (2009) stated 
that in 100 g raw tempe there is 205 ± 56 mg 
(dry weight) of isoflavone and the frying process 
would decrease the isoflavone by 45% to merely 
113 ± 41 mg per 100 g (dry weight) of fried tem-
pe. The correct tempe processing such as boiling 
or braising without frying or other processes that 
involve little fat could be considered as an alter-
native (Muaris 2016) in the optimation of tempe 
in obesity treatment diets. 
Daily consumption of tempe in adequate 
amounts could support the daily plant-based pro-
tein and isoflavone intake. In 1995, the US FDA 
declared that a minimum of 25 grams of plant-
based protein needs to be consumed daily as a 
part of a low fat and low cholesterol diet. Utari 
et al. (2011) suggested consumption of at least 
medium-sized slices of tempe (approximately 
150 grams of tempe/day) cooked by steaming or 
boiling to improve the lipid profile. Consump-
tion of that amount of tempe is equivalent to the 
consumption of 35 mg/day of isoflavone and is 
in line with the recommended daily isoflavone 
consumption which is 30-100 mg/day (Messina 
& Messina 2003). The effectiveness of tempe as 
a functional food in obesity cannot be achieved in 
a short time or with a certain dossage. Consum-
ing tempe regularly with appropriate processing 
in the long term should be incorporated in the 
healthy living habit.
CONCLUSION
Based on the literature study, it is known 
that soybeans are beneficial in the treatment of 
obesity and its complications. Soybeans help 
reduce body weight and improve the body lipid 
condition. The bioactive components which are 
presumed to play a role are soybean protein, pep-
tides, and isoflavone. The fermentation of soy-
beans into tempe can increase the amount and 
ability of these bioactive components. Optima-
tion and popularization of tempe consumption as 
a functional food in the daily diet, supported with 
correct tempe processing (without frying), could 
be a solution in obesity treatment. 
Table 4. Studies in humans pertaining to the effect of consuming soybeans and or tempe in obesity treat-
             ment (Astuti 1997)
Product Research method Results
Tempe formula-based food 24 volunteers (8 men, 16 wom-
en), daily consumption of a tem-
pe-based drink for three months 
A decline in total cholesterol (8.6% in men, 
10.25% in women), a decline in LDL (12% 
in men, 9.67% in women), a decline in MDA 
(23% in men, 15% in women).
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